Objective: To identify barriers to compliance of medical treatment for glaucoma among veterans. Methods: Patients with glaucoma from the Miami Veterans Affairs Eye Clinic (n¼74) filled out a 63-question survey regarding dry eye symptoms, concurrent systemic disease, and medications. The association between glaucoma medical compliance was defined as self-reported adherence to drop regimens greater than 75% of the time.
G laucoma, the second most common cause of world blindness, is an optic neuropathy that most commonly presents clinically with loss of peripheral visual field.
1,2 Sixty million people are estimated to have glaucomatous optic neuropathy. 1,2 Glaucoma carries with it a 9% risk of bilateral blindness and a 27% risk of unilateral blindness over 20 years. 3 Glaucomatous visual loss is incurable, but its progression can be mitigated with proper intraocular pressure control, which is the only modifiable risk factor proven to prevent the progression of glaucoma. 4 Current first-line therapy for glaucoma consists of daily drop regimens.
Compliance with topical therapies can significantly decrease the risk of blindness from glaucoma, but given its slow and asymptomatic progression, many patients are not motivated to comply. [4] [5] [6] [7] There are still many unknowns as to what factors contribute to noncompliance. Glaucoma severity, complexity of treatment regimen, and demographics (including gender, age, and race) have shown mixed results in their effects on compliance. [7] [8] [9] [10] [11] [12] [13] Medication cost has also been found as a barrier in some populations. 9, 11, 14 Our study population at the Department of Veteran Affairs (VA) has access to healthcare and medication coverage but is uniquely challenged with higher levels of anxiety disorders, particularity posttraumatic stress disorder (PTSD). [15] [16] [17] [18] [19] Little is known regarding the barriers to glaucoma treatment adherence among veterans, and as such, the objective of our study was to fill this knowledge gap by characterizing glaucoma compliance among veterans and identifying barriers to compliance.
METHODS

Study Population
The Miami VA eye clinic serves veterans with specific eye problems along with those needing surveillance because of medical conditions (e.g., diabetes). Patients on glaucoma medications who were seen in the Miami VA comprehensive eye clinic were invited to complete a 63-question survey at the time of their visit. This questionnaire inquired about patient information regarding compliance with glaucoma therapy, demographics, dry eye symptoms, medical conditions, and glaucoma treatment regimens. The questionnaire was self-administered, but assistance was available to those with literacy or vision issues. Inclusion criteria included the use of topical glaucoma medication. Exclusion criteria included any history of incisional glaucoma surgery. Of 77 patients meeting the inclusion criteria over an 8-week period, 74 (96%) filled out the survey.
Determination of Compliance
Patients were asked how frequently they missed taking their glaucoma medications. "Compliance" was defined as missing the medication less than 25% of the time, while missing 25% or more of the scheduled drops was considered to be "noncompliance."
Determination of Dry Eye Symptoms
The Dry Eye Questionnaire 5 (DEQ5) was used to ascertain the presence and severity of ocular surface symptoms. The DEQ5 is a dry eye-specific questionnaire consisting of five questions regarding the severity of eye discomfort, dryness, and tearing over a 1-month recall period. 20 The score ranges from 0 to 22 with zero-reflecting no-ocular surface symptoms and 22 reflecting a large number of symptoms. Per established guidelines, mild or greater dry eye symptoms were defined as a DEQ5 score of six or more. 20 
Compliance Difficulties
Difficulties with compliance including forgetfulness, intolerable side effects of glaucoma drops, self-reported poor quality of vision, and impact of drops on daily tasks were evaluated in the survey.
Data Collection
The VA ophthalmology service initiated this study as a quality improvement project. Miami VA Institutional Review Board's review and approval was later obtained to perform a chart review and link patient data to the questionnaires. The study was conducted in accordance with the principles of the Declaration of Helsinki. Data from the questionnaire was collected at the time of the respondents' visit and entered into a standardized database. The VA administrative database was used to collect other data such as patient demographics, including age, gender, ethnicity, and race.
Statistical Analysis
All statistical analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL) statistical package. Frequencies and descriptive analyses were performed. Categorical values were compared using chi square analysis; continuous variables were compared using the independent Student t test (for normally distributed variables) and Mann-Whitney test (for nonnormally distributed variables). Logistic regression analysis, with compliance as the dependent variable, was used to evaluate the association between various factors on compliance.
RESULTS
Study Population and Compliance
Of the 74 patients who filled out surveys, 80% (n¼59) of patients reported administering their drops more than 75% of the time. This was defined as the compliant group.
Demographics and Compliance
Our population primarily consisted of males with a mean age of 69 (SD 9.3). Demographic factors were not found to affect compliance as seen in Table 1 .
Dry Eye Symptoms and Compliance
Thirty-nine percent (n¼29) of patients reported mild or greater dry eye symptoms (DEQ5$6). These patients had reduced compliance with glaucoma medications compared with those without symptoms. Sixty-three percent (n¼17) of patients with dry eye symptoms were compliant with medications versus 89% (n¼42) of patients with no dry eye symptoms (P¼0.007). Table 2 demonstrates the dry eye symptom subscores, based on the 5-Item Dry Eye Questionnaire.
Comorbidities and Compliance
The average number of systemic medications prescribed to our patients was 8.8 (SD 5.8) . No relationship was seen between the total number of medications prescribed and compliance. A diagnosis of PTSD or anxiety was associated with decreased compliance (P¼0.02) ( Table 3) .
Glaucoma Regimens and Compliance
Differing glaucoma regimens did not play a significant role in compliance among our sample population ( Table 4 ). The mean number of glaucoma medications used by our patient population was 2.0 (SD 0.88). The most commonly used drops were latanoprost and the combination timolol/dorzolamide, 70% (52) and 46% (34), respectively. Those receiving assistance installing their drops had similar compliance (n¼49, 82%) to those who selfadministered their drops (n¼11, 79%; P¼0.39). Those using drops in both eyes were more compliant than those only using drops in one eye (compliance of n¼49, 88% versus n¼10, 56%, respectively [P¼0.003]).
Compliance Difficulties
Interestingly, although forgetfulness was the most common factor endorsed as a barrier to compliance, this issue was not found to be associated with noncompliance in our study population (P¼0.57). Patients who reported forgetting to refill their drops or leaving their drops at home when traveling were found to be less compliant. Patient-perceived quality of vision did not affect compliance. In addition, those who felt that the use of glaucoma drops interfered with work were found to be less compliant (Table 5) . 
Mental Health and Dry Eye Symptoms
Patients who endorsed PTSD and anxiety were more likely to complain of dry eye symptoms. Fifty-eight percent of those with PTSD (n¼7/12; P¼0.004) and 57% with anxiety (n¼8/14; P¼0.007) endorsed mild or greater dry eye symptoms (DEQ5$6) as compared to 34% and 32% without PTSD or anxiety, respectively. In a multivariate logistic regression analysis considering the effect of PTSD, anxiety, depression, and dry eye symptoms (DEQ5$6) on compliance, both the presence of PTSD and dry eye symptoms remained significant predictors for noncompliance. Posttraumatic stress syndrome portended a 4.9 times increased risk of noncompliance (95% confidence interval 1.08-21.83, P¼0.039), whereas dry eye symptoms portended a 6.3 times increased risk (95% confidence interval 1.69-23.16, P¼0.006).
DISCUSSION
Our study reveals that the majority of veterans being treated for glaucoma are compliant. Barriers to compliance were dry eye symptoms and underlying anxiety disorders (specifically PTSD and generalized anxiety disorder). Forgetfulness, despite being the most commonly endorsed barrier to compliance was not found to be associated with noncompliance.
Dry eye symptoms are known to be more prevalent among patients with glaucoma. Population-based studies show a 15% prevalence of dry eye symptoms. 21, 22 In contrast, dry eye symptoms have been reported in a higher frequency among patients with glaucoma seen in general ophthalmic clinics (39%-60%). [23] [24] [25] [26] [27] In our study, 39% of patients reported mild or greater dry eye symptoms, and this is consistent with previously published literature. Furthermore, the presence of dry eye symptoms was associated with decreased compliance. To our knowledge, this is the first study to demonstrate such a correlation and it substantiates the previous studies that have proposed that dry eye symptoms associated with glaucoma treatment leads to noncompliance. 24, 25, 28 The etiology of dry eye symptoms in glaucoma patients has been associated with the preservatives used in glaucoma drops, the most common being benzalkonium chloride (BAK). Benzalkonium chloride preserved ophthalmic solutions have been shown to cause inflammation, 29 tear film instability, 30 and disruption of the corneal epithelium. 31 Clinically, preserved glaucoma drops can cause foreign body sensation, burning, stinging, and dry eye sensation. [32] [33] [34] [35] [36] Furthermore, BAK has been shown to be neurotoxic, leading to decreased corneal innervation with corresponding decreased corneal sensitivity. 37 The extent of the neurotoxic effects of BAK has been shown to be time-and dose-dependent that can ultimately lead to a neurotrophic keratitis in a subset of patients who are chronically treated. 31, 37 The development of a neurotrophic cornea would further explain the lack of correlation between clinical signs and symptoms observed in patients treated for glaucoma. 38 It has been shown that the use of preservative free glaucoma drops can alleviate these effects, and it has been proposed that their use will increase compliance. [33] [34] [35] [36] 39, 40 In addition to dry eye symptoms, we found that a diagnosis of an underlying anxiety disorder, specifically PTSD and generalized anxiety disorder, led to decreased compliance. Anxiety disorders, particularly PTSD, are known to be more common among veterans. Population-based studies found that 8% of the general population will suffer from PTSD sometime in their life, whereas up to 20% of combat veterans are affected. 16, 41 This is consistent with our findings of 16% of veterans in our study carried a diagnosis of PTSD. Posttraumatic stress syndrome as a barrier to compliance does not appear to be unique to glaucoma treatment, and it has also been identified as a barrier to compliance with systemic medications. 42 A current theory as to why PTSD adversely influences medication compliance is based on PTSD-specific cognitive and behavioral symptoms. Avoidance is one of the key components in making the PTSD diagnosis, and it is thought that patients with PTSD may avoid following medical regimens because it reminds them of their initial trauma or of their mortality in general. 43 Previous studies have considered mental health variables and glaucoma compliance. A recent study among veterans with glaucoma and PTSD analyzed the medication in possession ratio and the follow-up ratio as a way of measuring medical compliance. They found that patients with PTSD tended to have more follow-ups with their ophthalmic care providers than others, but this did not translate into increased medications in possession. 44 Their study was inconclusive as to the effect that PTSD has on glaucoma drop compliance. In addition, a Greek study 45 evaluated the role of anxiety and depression on glaucoma treatment compliance. Depression was associated with noncompliance while anxiety did not significantly affect compliance. 45 In contrast, in our study, we found that anxiety was associated with noncompliance while depression trended toward significance.
Of note, in our study, and similar to previous publications, 46 ,47 dry eye symptoms and anxiety disorders correlated with one another. However, in a multivariate analysis, both PTSD and dry eye symptoms remained independent risk factors for noncompliance.
Previous studies have investigated potential modalities to improve compliance in patients with mental illness. Cognitive behavioral therapy, computer-automated reminders, and increasing patient education are strategies that have been shown to improve compliance among this patient population. [48] [49] [50] Based on these findings, we recommend that ophthalmologists spend time in educating patients and stressing the importance of treatment compliance. Another important strategy is collaboration with other medical providers, including mental health workers, in those with compliance issues. Further research is needed to assess what factors can improve the compliance in populations with a high burden of anxiety and depression.
As with all studies, this work has limitations, which need to be considered when interpreting the study results. First, this study used patient self-reporting to ascertain both the independent variables (anxiety, PTSD, dry eye symptoms) and the dependent variable (compliance). Second, we did not measure tear film parameters in this study. Although it is well known that symptoms and signs of dry eye are not well correlated, 38, 46 patients with glaucoma are known to have abnormalities in both, and our study design does not allow comment on how objective findings of dry eye may influence compliance. Finally, information from our patient population of elderly male veterans may not be generalizable to other, non-veteran populations. Further studies will be needed to re-evaluate our findings in female glaucoma populations and in other ethnic groups.
In conclusion, this study found that dry eye symptoms and mental disorders were associated with noncompliance to topical glaucoma medication regimens. These findings stress the importance of considering a patient's ocular surface symptoms and mental health status when prescribing glaucoma drops. Our study highlights the need for further collaboration with mental health workers and need for future research to assess what factors can improve compliance in this population, such as treatment of anxiety/depression, dry eye symptoms, and a more thorough discussion of why compliance is important in glaucoma.
